Amendments to the Claims

CLAIM:

1. (Currently Amended) A compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is $-C(R^{4c})=$ or $-N=$;

R^1 is ~~C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle~~ mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C_1-C_2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R^2 is hydrogen or methyl; ~~, C_1-C_3 alkyl optionally substituted with one to three fluoro substituents, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II~~



II

R^3 is hydrogen ~~or C_1-C_3 alkyl~~;

R^{4a} and R^{4b} are ~~independently~~ hydrogen~~, halo, or C_1-C_4 alkyl optionally substituted with one to three fluoro substituents~~;

When X is $-C(R^{4c})=$, R^{4c} is hydrogen~~, halo, or C_1-C_4 alkyl optionally substituted with one to three fluoro substituents~~;

R^5 is hydrogen ~~or C_1-C_3 alkyl optionally substituted with one to three fluoro substituents~~; and

R^6 is hydrogen ~~or C_1-C_3 alkyl optionally substituted with one to three fluoro substituents, provided that R^6 may be C_1-C_3 alkyl only when R^5 is other than hydrogen~~;

~~R^7 is hydrogen or C_1-C_6 alkyl optionally substituted with one to three halo substituents; and~~

~~n is an integer from 1 to 6 inclusively~~.

2. - 8. (Cancelled)

9. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutical carrier, diluent, or excipient.

10. - 13. (Cancelled)

14. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is $-C(R^{4c})=$ or $-N=$;

R^1 is ~~C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, substituted C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl-C_1-C_3 alkyl, substituted C_3-C_7 cycloalkyl-C_1-C_3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle~~ mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo, C_1-C_2 alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R^2 is hydrogen or methyl; ~~, C_1-C_3 alkyl optionally substituted with one to three fluoro substituents, C_3-C_6 cycloalkyl-C_1-C_3 alkyl, or a group of formula II~~



~~II~~

R^3 is hydrogen ~~or C_1-C_3-alkyl~~;

R^{4a} and R^{4b} are ~~independently~~ hydrogen~~, halo, or C_1-C_4-alkyl optionally substituted with one to three fluoro substituents~~;

When X is $-C(R^{4c})=$, R^{4c} is hydrogen~~, halo, or C_1-C_4-alkyl optionally substituted with one to three fluoro substituents~~;

R^5 is hydrogen ~~or C_1-C_3-alkyl optionally substituted with one to three fluoro substituents~~; and

R^6 is hydrogen ~~or C_1-C_3-alkyl optionally substituted with one to three fluoro substituents, provided that R^6 may be C_1-C_3-alkyl only when R^5 is other than hydrogen~~;

~~R^7 is hydrogen or C_1-C_6-alkyl optionally substituted with one to three halo substituents; and~~

~~n is an integer from 1 to 6 inclusively~~.

15. (Original) The method according to Claim 14 wherein the mammal is a human.

16. - 28. (Cancelled)

29. (New) A compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is –C(H)= or –N=;

R^1 is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R^2 is hydrogen or methyl;

R^3 is hydrogen;

R^{4a} and R^{4b} are hydrogen;

R^5 is hydrogen; and

R^6 is hydrogen.

30. (New) A pharmaceutical composition comprising a compound according to Claim 29 and a pharmaceutical carrier, diluent, or excipient.

31. (New) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



I;

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is –C(H)= or –N=;

R^1 is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R^2 is hydrogen or methyl;

R^3 is hydrogen;

R^{4a} and R^{4b} are hydrogen;

R^5 is hydrogen; and

R^6 is hydrogen.

32. (New) The method according to Claim 31 wherein the mammal is a human.